Tempus AI (NDQ:TEM) is another one of those early-stage NASDAQ biotechs hoping to go from the tens of billions into the hundreds of billions in market ...
Kymera Therapeutics (NDQ:KYMR) has a different drug development approach. Rather than find a protein involved in disease and ...
Why is the US stock market falling today? Nvidia, Tesla and Meta face pressure as AI spending fears, weak tech sentiment and rising oil prices hit Wall Street.
At Stocks Down Under, we're as concerned about the lack of ASX IPOs as private equity is. But this author's jaw dropped upon ...
The British business just grew sales 29%. Nick Scali (ASX:NCK) has told the market to expect underlying net profit after tax ...
Santos (ASX:STO) posted record 26.3 mmboe production and US$1.07bn free cash flow as Barossa and Pikka finally delivered.
Visit the website of BridgeBio Pharma (NDQ:BBIO), and you'll find it describes itself as 'a unique biotechnology company advancing genetic medicines via a ...
Ascendis Pharma (NDQ:ASND) has a portfolio of drugs that could be the most important to hit the market since BioMarin's Voxzogo (vosoritide). This became one ...
Wisr (ASX:WZR) upgrades FY27 Cash NPAT guidance 40% to at least A$7m as loan originations hit a record A$253.8m and the book ...
Fortescue (ASX:FMG) shipped 46.8Mt in Q1 FY27 but sold only 42.9Mt as the CMRG pricing dispute leaves inventory piling up.
CSL Limited (ASX:CSL) faces a Victorian shareholder class action over FY26 disclosure, creating a fresh overhang on the ...
Most investors meet a technology company through its financial statements. Revenue growth, gross margin, cash conversion — ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results